Real world data of the use of Faricimab in the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) in a multi-ethnic population: experience of first 1000 injections

Abstract

Purpose : Faricimab is the first and only bi-specific agent approved for the treatment of nAMD and DMO. There is little real-world data available on efficacy in multi-ethnic cohorts. This study presents real-world data of the first 1000 injections in a multi-ethnic population.

Methods : Prospective cohort study of treatment-naïve (TN) and treatment resistant (TR) patients treated with Faricimab for DMO and nAMD. Functional and structural parameters were documented at each visit for a loading regimen of 4 injections, and then at every visit based on a treat-and-extend regime. These included best-corrected visual acuity (BCVA), central sub-foveal thickness (CSFT), macular volume (MV), pigment epithelial detachment height (PED) for the nAMD cohort, intra- and sub-retinal fluid (IRF/SRF). Comparisons were made between data at initiation of Faricimab and the post-loading visit.

Results : nAMD:
188 eyes were included in the study (68% female, 34% Black and minority ethnic groups (BME); 36% TN). In the TN group, mean BCVA change from baseline was -0.09 LogMAR (-0.18, 0.01) (P 0.07); mean CSFT reduction was 122µm (-156, -88) (P<0.001); mean reduction in MV was 1.2µm³ (-1.5, -0.8) (P<0.001); mean change in PED height was -37µm (-53, -22) (P<0.001). 30% of TN eyes were dry after the first injection. In the TR group, mean changes in BCVA was 0.03 LogMAR (-0.03, 0.09) (P=0.31); mean change in CSFT was -23µm (-44, -2) (P<0.05); mean change in MV was -0.2µm³ (-0.5, 0.1) (P=0.1).

DMO:
122 eyes were included in the study (43% female, 86% BME, 63% TN). In the TN group, mean changes in BCVA was -0.15 LogMAR (-0.21, -0.09) (P<0.001); mean change in CSFT was -107µm (-139, -75) (P<0.001); mean change in MV was -1.1µm³ (-1.4, -0.8) (P<0.001). 20% of TN eyes had CSFT <280µm after the first injection. In the TR group, mean change in BCVA was -0.06 LogMAR (-0.10, -0.02) (P<0.01); mean change in CSFT was -74µm (-115, -32) (P=0.001); mean change in MV was -0.8µm³ (-1.2, -0.4) (P<0.001).

Conclusions : Our real-world experience of Faricimab for DMO and nAMD in a multi-ethnic cohort is encouraging. We will present time-to-dry analysis for the DMO and nAMD cohort. Longer term data is required to determine durability beyond 12-week interval and safety in this demographic.

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.